Corporate News Update – Black Diamond Therapeutics I (BDTX)
Black Diamond Therapeutics I (ticker BDTX) closed the trading session on Thursday, 22 October 2026 at a modest rise of 0.48 %, with the final price settling around USD 2.09 on the Nasdaq exchange. The stock’s movement reflects a gradual upward trajectory, having gained 5.05 % since the close of last month.
Trading Metrics and Market Position
- Current Share Price: USD 2.09
- Market Capitalisation: USD 116.3 million
- Shares Outstanding: 57.5 million
- 24‑Hour Trading Volume: Approximately USD 4.9 million worth of shares exchanged
- Simple Moving Average (200 days): USD 2.22
The stock’s price has seen a notable swing over the past year, peaking at USD 4.94 on 12 November 2025 and dipping to a low of USD 1.60 on 13 October 2026. This volatility underscores the company’s position as a small‑cap player in the highly competitive biotechnology sector.
Recent Performance in Context
In the same 24‑hour period, several peer and related securities experienced a mix of gains and losses:
| Symbol | Recent % Change | Current Price (USD) | Market Capitalisation (USD) |
|---|---|---|---|
| KRRO (Korro Bio) | –1.59 % | 11.19 | 139.0 mn |
| BMN (Blackrock 2037 Muni Trm) | –0.62 % | 22.47 | 137.5 mn |
| SCPQ (Social Commerce Partner Cl) | +0.90 % | 10.14 | 137.5 mn |
| EARN (Ellington Credit) | –1.69 % | 3.58 | 137.6 mn |
| CUE (Cue Biopharma) | +11.21 % | 19.36 | 137.7 mn |
While BDTX’s movement was modest, Cue Biopharma’s significant 11.21 % surge illustrates the high volatility that can characterize biotech stocks, particularly those engaged in niche therapeutic development.
Company Overview
Black Diamond Therapeutics, Inc. is a biotechnology firm headquartered in Cambridge, United States. The company focuses on developing pharmacotherapies for patients with genetically‑defined cancers, targeting a specific subset of oncology patients within the United States. Its products are currently under development, and the company maintains an active presence on the Nasdaq stock exchange. For more information, the company’s official website can be visited at www.blackdiamondtherapeutics.com .
Regulatory Update: Ellington Credit Co.
Ellington Credit Co. (EARN) filed a notice of effectiveness with the U.S. Securities and Exchange Commission on 21 October 2026. The filing confirms the company’s full compliance under the Securities Act of 1933 and formalises its transition from “Ellington Residential Mortgage REIT” to its current name. The notice also updates the company’s contact details and confirms the effective date of the name change. No additional financial details or performance metrics were disclosed in the submission.
Bottom Line
Black Diamond Therapeutics I remains a small‑cap entity within the biotechnology arena, with a current price that reflects cautious investor sentiment. The company’s modest gains in the recent trading session are tempered by its broader market volatility and the competitive landscape of cancer therapeutics. Investors and market analysts should continue to monitor the firm’s clinical development milestones and regulatory approvals, which will likely play a decisive role in shaping its future trajectory.
